By Simpson Global Media News Desk
The Federal Government has renewed its push to expand Nigeria’s domestic pharmaceutical manufacturing capacity, setting a target of producing at least 70 per cent of essential healthcare products locally by 2030 as the country seeks to reduce dependence on imported medicines and strengthen its ability to withstand disruptions in global supply chains.
The Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, disclosed the target on Monday, September 28, 2026, while declaring open the eighth Nigeria Pharma Manufacturers Expo at Harbour Point Event Centre in Victoria Island, Lagos.
The two-day event, organised by the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria, brings manufacturers, regulators, investors, technology providers, researchers and other industry stakeholders together around the theme, “Regional Manufacturing: Advancing Africa’s Pharma and Life-Science Sovereignty through Localization.”
The Federal Ministry of Health and Social Welfare said the government sees local pharmaceutical manufacturing as a strategic component of medicine security, healthcare resilience and broader economic development.
Salako said the experience of the COVID-19 pandemic, together with continuing changes in international healthcare financing and supply chains, had demonstrated the risks associated with relying heavily on overseas sources for medicines and other health commodities.
According to the ministry, the government’s approach is not limited to increasing the number of medicines manufactured in Nigeria. It also includes efforts to develop local capacity in active pharmaceutical ingredients, vaccines, biologics, diagnostics, research, quality assurance, packaging and distribution.
The minister said the Presidential Initiative to Unlock the Healthcare Value Chain, known as PVAC, had attracted commitments of about $2 billion at single-digit interest rates, with approximately 50 Nigerian health companies in advanced funding discussions.
He also said 87 local manufacturers were benefiting from the implementation of a Presidential Executive Order providing zero tariffs on pharmaceutical machinery, active pharmaceutical ingredients and excipients across almost 1,000 Harmonised System codes.
The government’s stated objective is to move Nigeria progressively from importing finished pharmaceutical products towards developing a deeper domestic production ecosystem.
From medicine access to medicine security
For decades, Nigeria’s pharmaceutical market has depended substantially on imported medicines and manufacturing inputs.
That dependence can become more significant during international crises, currency pressures, disruptions to shipping routes, shortages of raw materials or changes in the policies of major producing countries.
The Federal Ministry of Health said the lesson from the COVID-19 pandemic was that access to medicines cannot be considered only in terms of whether products are available in international markets under normal conditions.
Salako argued that Nigeria must also consider whether it can continue supplying essential products when international supply chains are disrupted.
That distinction is central to the government’s current medicine-security strategy.
The minister said medicine security should be viewed as a national resilience issue rather than solely as a health-sector concern. The ministry said Nigeria needs stronger domestic capacity to manufacture medicines, vaccines, diagnostics and other critical health technologies.
The government’s position places pharmaceutical manufacturing alongside hospitals, laboratories, research centres and supply chains as part of the infrastructure needed for a resilient health system.
The approach also reflects a broader shift in health policy discussions across Africa, where governments and regional institutions have increasingly focused on reducing vulnerabilities created by dependence on imported medicines and medical technologies.
For Nigeria, the size of its population and the scale of its healthcare needs make the issue particularly significant.
A stronger local manufacturing base could potentially reduce exposure to international supply disruptions, while also creating opportunities for industrial investment, technical employment, research and regional exports.
But the transition requires more than government targets.
Manufacturers need reliable power, access to finance, raw materials, modern equipment, predictable regulation, efficient logistics and sufficient market demand. They also need the ability to produce medicines consistently at internationally acceptable quality standards.
Government outlines the production strategy
The Federal Government is pursuing the 70 per cent target through several policy measures.
One of the principal instruments identified by the Ministry of Health is the Presidential Initiative to Unlock the Healthcare Value Chain.
The ministry said the initiative had secured about $2 billion in commitments at single-digit interest rates, while roughly 50 Nigerian health companies were in advanced discussions for funding.
The initiative is intended to support investment throughout the healthcare value chain rather than concentrating solely on final pharmaceutical formulation.
Another important instrument is the Presidential Executive Order for Pharmaceutical and Allied Sectors.
According to Salako, the order has enabled 87 local manufacturers to benefit from zero tariffs on pharmaceutical machinery, active pharmaceutical ingredients and excipients covering almost 1,000 Harmonised System codes.
The ministry said the order contains both fiscal and non-fiscal measures intended to encourage domestic production.
Tariff relief can reduce the cost of importing machinery and production inputs that are not yet sufficiently available domestically. The longer-term objective, however, is to expand local capacity so that more of those inputs can eventually be produced within Nigeria.
That distinction is important because local assembly alone does not necessarily amount to full manufacturing independence.
A pharmaceutical product may be formulated and packaged in Nigeria while its active ingredient, excipients, specialised equipment or other critical inputs are sourced abroad.
The Federal Government therefore says its localization policy must progressively extend further upstream.
Building capacity beyond finished medicines
Salako specifically called for greater investment in research and development and highlighted Nigeria’s phytomedicinal resources as an area with potential for further development.
The government also pointed to the operationalisation of the NIPRD API Capacity Building and Concept Production Centre and efforts to develop commercial active pharmaceutical ingredient manufacturing capacity.
APIs are the components responsible for the therapeutic effect of medicines. Their availability is therefore central to pharmaceutical production.
If manufacturers continue to depend heavily on imported APIs, Nigeria’s vulnerability to international supply disruptions can remain even when finished medicines are produced locally.
The ministry also identified efforts to localise production of diagnostic products for HIV, hepatitis and syphilis.
Diagnostics are an important part of healthcare delivery because the availability of medicines alone does not guarantee effective treatment. Health workers also need reliable tools to identify diseases and monitor patients.
The Federal Government said it is therefore seeking to develop a broader ecosystem that connects research, raw materials, pharmaceutical formulation, quality control, manufacturing, packaging and distribution.
Salako cautioned that localization should not simply involve bringing imported ingredients and technologies into Nigeria and assembling finished products locally.
He said the objective is to progressively build capabilities across the entire value chain.
That would represent a more demanding form of industrial development, requiring investment in scientific research, engineering, skilled workers, quality laboratories, regulatory systems and manufacturing infrastructure.
The industry’s perspective
The pharmaceutical manufacturing industry has previously identified both opportunities and obstacles in the drive towards greater local production.
The Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria said in August that it was targeting 70 per cent local drug production.
At a briefing ahead of the September 28–29 expo, the group called for measures to reduce energy costs and improve the operating environment for pharmaceutical manufacturers.
Channels Television reported that PMG-MAN said the sector had grown from 20 pioneer members in 1983 to more than 200 manufacturing companies. The group also cited National Agency for Food and Drug Administration and Control data indicating that imported finished pharmaceutical volumes had fallen from 4.03 billion units to 1.13 billion units by 2025.
The figures, as presented by the industry group, point to an expanding role for domestic manufacturers. They do not, however, mean Nigeria has eliminated dependence on imports.
The manufacturers have argued that the next stage of development will require sustained policy support and investment.
Among the concerns raised by PMG-MAN is the cost of electricity.
The group said some pharmaceutical companies were spending more than 40 per cent of revenue on electricity and alternative power generation. It contrasted that with lower energy-cost burdens reported for manufacturers in countries such as China and India.
Energy costs matter particularly for pharmaceutical manufacturing because factories require controlled production environments, refrigeration, water treatment, laboratory systems, ventilation, clean-room technology and other equipment that must operate reliably.
An unstable or expensive power supply can therefore affect both production costs and competitiveness.
PMG-MAN has also called for stronger policies supporting domestic production of active pharmaceutical ingredients and other essential inputs.
The manufacturers have argued that longer periods of policy stability would make it easier for companies to plan major capital investments.
The group previously called for the two-year cycle of the pharmaceutical executive order to be extended to a five-year framework, saying longer-term policy certainty could support investment decisions.
Why the 70 per cent target matters
The 2030 target places a measurable figure on the government’s localization ambition.
Rather than simply saying Nigeria wants more medicines produced domestically, the government is now working towards having at least 70 per cent of essential healthcare products produced within the country by the end of the decade.
The target will require clarity over what products are included, how local production will be measured and how progress will be reported.
It will also require a sustained increase in manufacturing capacity.
Essential medicines cover a wide range of products, including treatments for infectious diseases, chronic illnesses and other common health conditions.
Different medicines have different manufacturing requirements.
Some can be formulated using relatively established processes, while others require specialised technologies, sophisticated quality-control systems or highly regulated biological production.
Vaccines and biologics, for example, require specialised facilities and scientific expertise. Diagnostic products also require specialised manufacturing and validation systems.
The government’s inclusion of APIs, vaccines, biologics and diagnostics in its broader strategy therefore indicates that the intended transformation extends beyond conventional tablet and capsule production.
The role of finance
Access to long-term, reasonably priced finance is another central part of the localization effort.
Pharmaceutical manufacturing requires substantial upfront investment in factories, machinery, clean rooms, laboratories, quality-control systems, storage facilities and distribution networks.
Returns on those investments may take years to materialise.
The Federal Ministry of Health said the PVAC initiative had attracted about $2 billion in commitments at single-digit interest rates, with about 50 Nigerian health firms in advanced funding discussions.
If these commitments translate into actual investments, they could provide additional capital for factory expansion, equipment upgrades and new manufacturing facilities.
The government’s policy challenge will be to ensure that financing reaches productive projects capable of meeting regulatory standards and supplying medicines competitively.
Manufacturers, meanwhile, must demonstrate that investments can translate into consistent output, quality and market supply.
Finance alone cannot solve the sector’s structural problems.
A company may obtain capital to build a factory, for example, but still face high operating costs if electricity, logistics, imported inputs and regulatory processes remain expensive.
The success of the policy will therefore depend on whether multiple parts of the operating environment improve at the same time.
Creating a predictable domestic market
The government is also looking at the demand side of pharmaceutical manufacturing.
Salako highlighted the establishment of Medipool, described by the ministry as Nigeria’s national Group Purchasing Organisation for essential medicines and medical commodities.
The stated purpose is to aggregate procurement, negotiate bulk purchases and improve supply-chain efficiency.
The government believes such an arrangement could provide more predictable and large-scale demand for domestic manufacturers.
That could be important for companies deciding whether to invest in additional production capacity.
Manufacturing economics depend not only on the ability to produce goods but also on whether companies can sell sufficient quantities to operate factories efficiently.
Large and predictable orders can help manufacturers plan production, manage inventories and justify investments in equipment and workforce development.
However, procurement systems must also maintain appropriate standards for quality, price, transparency and supply reliability.
The objective is not simply to favour local products regardless of quality or cost, but to develop manufacturers capable of meeting national needs competitively.
Regulation remains central
A larger domestic pharmaceutical industry will also require effective regulation.
Medicines are safety-sensitive products, and expanding local production must occur alongside rigorous quality assurance.
The National Agency for Food and Drug Administration and Control plays a central role in regulating medicines and other health products in Nigeria.
Manufacturers must meet applicable requirements covering production, quality control, registration, labelling and other regulatory processes.
The challenge is to ensure that regulatory systems are sufficiently rigorous to protect patients while also being efficient enough to support legitimate manufacturing and investment.
The Federal Government’s broader localization strategy therefore includes regulatory alignment and capacity building.
At the regional level, the government is also looking towards the African Continental Free Trade Area as a means of expanding the potential market for Nigerian pharmaceutical manufacturers.
Nigeria has one of Africa’s largest consumer markets. If local companies can achieve internationally competitive quality and pricing, regional trade could provide additional demand beyond the domestic market.
The pharmaceutical expo’s regional focus reflects this ambition.
Its theme, according to the organisers and the Ministry of Health, centres on regional manufacturing and advancing African pharmaceutical and life-science sovereignty through localization.
Regional markets and AfCFTA
For pharmaceutical manufacturers, the African Continental Free Trade Area presents both an opportunity and a challenge.
A wider regional market can allow companies to achieve economies of scale that may be difficult to achieve by selling only within one national market.
Larger production runs can potentially reduce unit costs, while regional distribution can help manufacturers spread investment across several markets.
But regional expansion also requires compliance with the regulatory requirements of different countries.
Differences in product registration, standards, customs procedures and market-access rules can increase costs for manufacturers seeking to export.
The government therefore wants greater regulatory alignment alongside regional market integration.
The ultimate objective is for Nigeria to become not only a consumer of pharmaceutical products but also a significant production and distribution centre within Africa.
That would require manufacturers to compete on quality, price, reliability and delivery.
Research and the Nigerian knowledge base
Another component of the strategy is research.
The Federal Ministry of Health has called for greater investment in research and development, including the study and potential development of Nigeria’s phytomedicinal resources.
Nigeria has a substantial body of traditional knowledge concerning medicinal plants, but translating that knowledge into modern pharmaceutical products requires scientific research, clinical evidence, standardisation, quality control and regulatory approval.
The government’s broader localization objective could therefore connect universities, research institutes, manufacturers and regulators more closely.
The NIPRD API Capacity Building and Concept Production Centre is one of the facilities identified by the ministry as part of the effort to expand domestic technical capability.
Such institutions can help bridge the gap between scientific research and commercial production.
However, sustained funding and collaboration will be necessary if research discoveries are to move beyond laboratories into products that can be manufactured at scale.
What manufacturers need to deliver
While government policy is important, the industry itself will also determine whether the 2030 target is achieved.
Manufacturers will need to invest in modern equipment, skilled personnel, quality systems, research and development and efficient production processes.
They will also need to demonstrate that local products can meet the quality standards required by Nigerian consumers, hospitals and health programmes.
The industry’s previous call for lower energy costs illustrates the scale of the challenge.
If manufacturers spend a large proportion of their revenue on power generation, resources that could otherwise be used for research, expansion or workforce development are absorbed by operating costs.
Similarly, delays in clearing imported machinery or essential production inputs can interrupt manufacturing schedules.
Local production cannot be strengthened simply by encouraging companies to build factories.
The wider industrial ecosystem must make it possible for those factories to operate competitively.
That includes transport infrastructure, power, ports, financing, customs procedures, laboratory capacity, skilled personnel, regulatory systems and access to markets.
Medicine security and public health
The importance of local pharmaceutical manufacturing ultimately comes back to patients.
When essential medicines are unavailable or become too expensive, patients can delay treatment, interrupt medication or turn to unregulated sources.
A reliable domestic supply does not automatically guarantee affordability, but it can reduce some of the vulnerabilities associated with external supply disruptions.
For chronic diseases, continuity of medicine supply is particularly important because patients may require treatment over long periods.
For infectious diseases and public-health emergencies, rapid access to medicines and diagnostics can also become critical.
A domestic manufacturing base can potentially shorten some supply chains and provide greater national control over production.
At the same time, local production must be accompanied by effective distribution.
Medicines manufactured in Nigeria still need to reach hospitals, pharmacies, primary healthcare centres and patients across the country.
Warehousing, transportation, inventory management and procurement therefore remain part of medicine security.
The Federal Ministry of Health’s emphasis on supply chains and Medipool reflects this broader understanding.
Lessons from COVID-19
The government’s current approach is partly shaped by the experience of the COVID-19 pandemic.
The pandemic exposed weaknesses in global supply chains as countries competed for medicines, vaccines, protective equipment and other health commodities.
Countries that depended heavily on international markets faced uncertainty over availability and delivery.
The Federal Ministry of Health has cited those disruptions as one reason Nigeria needs stronger domestic production capacity.
The objective is not necessarily to manufacture every medicine and medical technology domestically.
Instead, the government is seeking greater capacity in strategically important areas and stronger resilience across the supply chain.
That distinction matters because complete self-sufficiency may not be practical or economically efficient.
International trade will continue to play a role in Nigeria’s pharmaceutical sector.
The policy question is therefore how to balance international sourcing and regional trade with sufficient domestic capability to reduce strategic vulnerabilities.
Investment opportunities
The localization drive could also create opportunities for investment.
The government’s reported $2 billion in commitments under PVAC, together with the participation of dozens of firms in funding discussions, indicates an effort to mobilise private capital.
Potential investment areas include pharmaceutical formulation, API production, vaccine and biologics manufacturing, diagnostics, laboratory equipment, packaging, cold-chain systems, warehousing and distribution.
Technology partnerships could also help Nigerian manufacturers improve production efficiency and quality.
The pharmaceutical expo provides a platform for companies to meet technology suppliers and investors, while the industry’s regional focus could create opportunities for cross-border partnerships.
However, investment decisions will depend on the underlying business environment.
Companies need confidence that policies will remain predictable, that markets will function, that infrastructure will support production and that regulatory systems will operate efficiently.
The workforce challenge
Expanding pharmaceutical production will also require more skilled workers.
Pharmacists, chemists, microbiologists, engineers, laboratory scientists, quality-assurance professionals, regulatory specialists, technicians and production managers all have roles in a modern pharmaceutical manufacturing system.
Universities and technical institutions will therefore need to align training with the needs of a growing manufacturing sector.
The industry’s expansion from the small number of pioneer manufacturers in the early 1980s to more than 200 companies cited by PMG-MAN indicates that the sector already has a substantial industrial base.
The next stage could require an even wider technical workforce as companies adopt more sophisticated manufacturing systems.
This also creates an opportunity to retain skilled professionals within Nigeria by providing career paths in manufacturing, research, quality control and regulatory affairs.
The importance of implementation
The 70 per cent target is ambitious, but targets alone do not change supply chains.
Implementation will be the key test.
The government has already identified several measures: financing through PVAC, tariff relief for machinery and inputs, API capacity development, support for vaccines and diagnostics, procurement reform through Medipool and regional market expansion.
The next question is how consistently those measures will be implemented and whether they will translate into measurable increases in domestic capacity.
Manufacturers will also be watching the stability of government policies.
Large pharmaceutical projects can take years to plan, finance, construct, validate and bring into commercial operation.
Investors therefore need confidence that incentives and regulatory frameworks will remain sufficiently predictable over the life of those projects.
The industry’s request for a longer policy horizon reflects this concern.
Measuring progress towards 2030
To assess progress towards the 70 per cent target, Nigeria will need reliable and transparent measurements.
The government will need to identify which essential healthcare products are currently manufactured domestically, which remain predominantly imported and where the largest production gaps exist.
It will also need to distinguish between final formulation and deeper domestic manufacturing.
For example, a medicine packaged in Nigeria using imported active ingredients may count as a locally manufactured product under some definitions, but it does not provide the same degree of supply-chain resilience as a product whose critical inputs are also produced domestically.
The government’s own emphasis on the entire value chain suggests that deeper localization is the intended direction.
Progress could therefore be assessed through indicators such as domestic manufacturing capacity, API production, vaccine and biologics capacity, diagnostic manufacturing, investment levels, production volumes, product quality, export performance and the reliability of supply.
Transparent reporting would allow policymakers, manufacturers and the public to see where progress is being made and where additional intervention is required.
What happens next
The eighth Nigeria Pharma Manufacturers Expo runs from September 28 to September 29 in Lagos and is bringing together pharmaceutical manufacturers, regulators, investors, suppliers and other stakeholders to discuss production and technology issues.
The event provides an immediate platform for industry discussions around the government’s 2030 objective.
The Federal Ministry of Health is expected to continue implementing measures linked to the Presidential Initiative to Unlock the Healthcare Value Chain and the pharmaceutical executive order.
The ministry has also signalled continued work on API production, vaccines, biologics, diagnostics and health-commodity supply chains.
For manufacturers, the next phase will involve turning policy incentives into new investments, expanded production lines, improved technology and stronger domestic supply.
For regulators, the challenge will be maintaining quality and safety while creating efficient pathways for legitimate manufacturers.
For investors, the key issue will be whether Nigeria’s market size and policy direction can support commercially sustainable pharmaceutical businesses.
And for patients, the ultimate measure will be whether the changes lead to more reliable availability of safe, effective and affordable medicines.
A broader industrial question
Nigeria’s pharmaceutical ambitions extend beyond the health sector.
The effort to produce more medicines domestically raises broader questions about industrial policy, research capacity, energy infrastructure, investment, trade and economic resilience.
Pharmaceutical manufacturing is a highly regulated and technically demanding industry, making it an important test of Nigeria’s ability to develop complex domestic production capabilities.
If the country can strengthen the full chain—from research and raw materials to manufacturing, quality assurance, packaging and distribution—it could create capabilities that extend beyond individual medicines.
The same infrastructure can support laboratory science, biotechnology, diagnostics, engineering and other areas of the life-sciences economy.
The government has therefore presented pharmaceutical localization not merely as a programme for replacing imports but as part of a broader effort to build domestic productive capacity.
Salako said Nigeria should move from dependence towards capability and from fragmented markets towards regional scale, linking the country’s pharmaceutical development to the wider African market.
The road to 2030
Nigeria now has less than four years to reach the government’s stated 2030 target.
Achieving 70 per cent local production of essential healthcare products would require sustained investment and coordination across government, industry, research institutions, regulators and development partners.
The starting point is not zero.
Nigeria already has an established pharmaceutical manufacturing sector, regulatory institutions, research organisations and a large domestic market.
The government says its recent interventions are designed to build on those foundations.
But the remaining gaps are substantial, particularly in critical inputs, energy costs, advanced manufacturing technologies, financing, infrastructure and regional market access.
The September 28 announcement therefore represents a policy direction rather than evidence that the 70 per cent target has already been achieved.
The government’s reported commitments, including about $2 billion under PVAC and funding discussions involving approximately 50 health firms, provide an indication of the scale of capital being mobilised. The effectiveness of those commitments will ultimately depend on how quickly projects become operational and how much additional production capacity they create.
The same applies to tariff incentives.
Removing tariffs on pharmaceutical machinery, APIs and excipients can reduce some costs, but manufacturers will still face energy, logistics, financing and regulatory expenses.
The industry’s own demands show that manufacturers consider those operational conditions important to competitiveness.
A test of health-system resilience
The drive for pharmaceutical localization comes at a time when health systems globally are increasingly concerned about supply-chain resilience.
Nigeria’s population, healthcare needs and regional economic position give it a potentially important role in African pharmaceutical production.
But achieving that role will require more than importing technology and assembling products.
It will require investment in people, research, raw materials, factories, laboratories and distribution networks.
It will also require a regulatory environment capable of ensuring that growth in production does not come at the expense of medicine quality or patient safety.
The Federal Government has now placed a clear numerical objective on the agenda: 70 per cent local production of essential healthcare products by 2030.
Whether Nigeria reaches that level will depend on the implementation of the policies announced, the scale and quality of private-sector investment, the ability of manufacturers to overcome high operating costs, and the country’s capacity to develop deeper pharmaceutical capabilities.
For now, the September 28 announcement signals an intensification of that effort.
The government is seeking to use financing, tariff measures, procurement reforms, research infrastructure and regional trade opportunities to move Nigeria towards greater pharmaceutical manufacturing capacity.
The industry, meanwhile, is calling for a business environment capable of sustaining investment.
The outcome will have implications beyond pharmaceutical companies.
It will affect the resilience of Nigeria’s healthcare supply chain, the availability of essential medicines, the development of domestic scientific and industrial skills, and the country’s capacity to respond when international supply chains come under pressure.
As the 2030 deadline approaches, the central issue will increasingly shift from policy announcements to measurable production: how many more medicines are being made in Nigeria, how much of their critical inputs are locally sourced, how competitive the products are, and whether patients can consistently obtain them when they need them.
Those indicators will ultimately determine how far Nigeria has moved from dependence towards the medicine security and domestic manufacturing capacity that the Federal Government says it is seeking to build.
Comments
Post a Comment